MetaCap

Cardio Diagnostics (CDIO) vs Trinity Biotech (TRIB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Trinity Biotech is the larger company by market cap ($5.1 million vs $4.7 million), about 1.1 times the size. Trinity Biotech converts more of its revenue into profit, with a net margin of -51.6% versus -43832.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDIO-18.37%TRIB-7.56%
+23%+0%-23%
Oct 7, 20261 yearNov 20, 2026
CDIO-14.44%TRIB-8.97%
+19%+0%-19%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDIO versus TRIB key metrics
MetricCDIOTRIB
Share price$1.60$6.24
Market cap$4.74M$5.07M
1-day change-3.03%+13.76%
EPS (TTM)$-2.52$-60.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.82K$61.55M
Revenue growth (YoY)-57.51%+8.31%
Net income (latest FY)$-6.50M$-31.79M
Gross margin—34.83%
Operating margin-43737.46%-34.38%
Net margin-43832.49%-51.64%
52-week high$7.91$52.50
52-week low$0.97$4.54
Distance from 52-week high-79.77%-88.11%
Average volume26.91K13.54K
Shares outstanding2.96M813.13K
Employees15287
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Trinity Biotech is more profitable, keeping -51.6 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
  • Trinity Biotech grew revenue faster in its latest fiscal year (+8.31% vs -57.51%).

About Cardio Diagnostics

CDIO stock →

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees

About Trinity Biotech

TRIB stock →

Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees

CDIO vs TRIB FAQ

Which is bigger, Cardio Diagnostics or Trinity Biotech?

Trinity Biotech (TRIB) is larger, with a market capitalization of $5.07M compared with $4.74M for Cardio Diagnostics (CDIO).

Are Cardio Diagnostics and Trinity Biotech in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons